BR112018073221A2 - métodos de previsão da utilidade de proteínas ou seus fragmentos, métodos de seleção e/ou avaliação de modificações de aminoácidos específicas, método de fornecimento de vacinas e vacina - Google Patents

métodos de previsão da utilidade de proteínas ou seus fragmentos, métodos de seleção e/ou avaliação de modificações de aminoácidos específicas, método de fornecimento de vacinas e vacina

Info

Publication number
BR112018073221A2
BR112018073221A2 BR112018073221-4A BR112018073221A BR112018073221A2 BR 112018073221 A2 BR112018073221 A2 BR 112018073221A2 BR 112018073221 A BR112018073221 A BR 112018073221A BR 112018073221 A2 BR112018073221 A2 BR 112018073221A2
Authority
BR
Brazil
Prior art keywords
methods
vaccine
fragments
selecting
amino acid
Prior art date
Application number
BR112018073221-4A
Other languages
English (en)
Inventor
VORMEHR Mathias
Sahin Ugur
SCHRÖRS Barbara
Löwer Martin
Boegel Sebastian
Original Assignee
Biontech Rna Pharmaceuticals Gmbh
Tron - Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberg-Universität Mainz Gemeinnützige Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Rna Pharmaceuticals Gmbh, Tron - Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberg-Universität Mainz Gemeinnützige Gmbh filed Critical Biontech Rna Pharmaceuticals Gmbh
Publication of BR112018073221A2 publication Critical patent/BR112018073221A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

a presente invenção refere-se a métodos de previsão de peptídeos ou polipeptídeos, tais como epítopos de células t, úteis para imunoterapia, tal como para vacinação. particularmente, a presente invenção refere-se a métodos de previsão se peptídeos ou polipeptídeos, tais como epítopos ou antígenos associados a tumores, particularmente neoepítopos ou neoantígenos associados a tumores, são imunogênicos e, particularmente, úteis para imunoterapia, tal como para vacinação. os métodos de acordo com a presente invenção podem ser particularmente utilizados para fornecimento de vacinas que são específicas para tumores de pacientes e, portanto, no contexto de vacinas contra o câncer personalizadas.
BR112018073221-4A 2016-05-13 2017-05-10 métodos de previsão da utilidade de proteínas ou seus fragmentos, métodos de seleção e/ou avaliação de modificações de aminoácidos específicas, método de fornecimento de vacinas e vacina BR112018073221A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2016/060897 WO2017194170A1 (en) 2016-05-13 2016-05-13 Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
EPPCT/EP2016/060897 2016-05-13
PCT/EP2017/061196 WO2017194610A1 (en) 2016-05-13 2017-05-10 Methods for predicting the usefulness of proteins or protein fragments for immunotherapy

Publications (1)

Publication Number Publication Date
BR112018073221A2 true BR112018073221A2 (pt) 2019-02-19

Family

ID=55971007

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018073221-4A BR112018073221A2 (pt) 2016-05-13 2017-05-10 métodos de previsão da utilidade de proteínas ou seus fragmentos, métodos de seleção e/ou avaliação de modificações de aminoácidos específicas, método de fornecimento de vacinas e vacina

Country Status (25)

Country Link
US (1) US20190178871A1 (pt)
EP (2) EP3792628B1 (pt)
JP (2) JP2019520554A (pt)
KR (2) KR102358620B1 (pt)
CN (1) CN109073637A (pt)
AU (2) AU2017264546B2 (pt)
BR (1) BR112018073221A2 (pt)
CA (1) CA3022654A1 (pt)
CY (1) CY1123520T1 (pt)
DK (1) DK3455625T3 (pt)
ES (1) ES2826480T3 (pt)
HR (1) HRP20201671T1 (pt)
HU (1) HUE052240T2 (pt)
IL (2) IL300841A (pt)
LT (1) LT3455625T (pt)
MA (1) MA43794B1 (pt)
MD (1) MD3455625T2 (pt)
MX (2) MX2018013081A (pt)
PL (1) PL3455625T3 (pt)
PT (1) PT3455625T (pt)
RS (1) RS61071B1 (pt)
SG (1) SG11201808495SA (pt)
SI (1) SI3455625T1 (pt)
WO (2) WO2017194170A1 (pt)
ZA (1) ZA201805809B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112812153B (zh) * 2018-02-15 2022-06-14 国立大学法人旭川医科大学 癌症抗原肽
CN109021062B (zh) * 2018-08-06 2021-08-20 倍而达药业（苏州）有限公司 一种肿瘤新抗原的筛选方法
CN111621564B (zh) * 2019-02-28 2022-03-25 武汉大学 一种鉴定有效肿瘤新抗原的方法
CN110534156B (zh) * 2019-09-02 2022-06-17 深圳市新合生物医疗科技有限公司 一种提取免疫治疗新抗原的方法及***
CN111487399B (zh) * 2020-03-26 2021-09-17 湖南师范大学 一种蛋白分子标记在鱼类生殖细胞发育研究中的应用
CN117999355A (zh) 2021-08-24 2024-05-07 生物技术欧洲股份公司 体外转录技术
WO2024083345A1 (en) 2022-10-21 2024-04-25 BioNTech SE Methods and uses associated with liquid compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2766205B1 (fr) * 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
CA2603191A1 (en) * 2005-03-29 2006-10-05 The Board Of Trustees Of The University Of Illinois Cancer vaccines and therapeutic methods
JP2009273377A (ja) * 2008-05-12 2009-11-26 Igaku Seibutsugaku Kenkyusho:Kk Ｍｈｃクラスｉ分子と結合し癌細胞の表面に表出されるペプチド候補の選択方法
TW201000119A (en) * 2008-06-10 2010-01-01 Oncotherapy Science Inc MYBL2 epitope peptides and vaccines containing the same
PL2172211T3 (pl) * 2008-10-01 2015-05-29 Immatics Biotechnologies Gmbh Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka
MX2012004721A (es) * 2009-10-23 2012-06-25 Mannkind Corp Inmunoterapia de cancer y metodo de tratamiento.
US9266922B2 (en) * 2011-06-01 2016-02-23 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antigen peptide and uses thereof

Also Published As

Publication number Publication date
CY1123520T1 (el) 2022-03-24
EP3455625B1 (en) 2020-09-02
IL262680B1 (en) 2023-04-01
JP2019520554A (ja) 2019-07-18
KR20190008218A (ko) 2019-01-23
RS61071B1 (sr) 2020-12-31
SI3455625T1 (sl) 2021-01-29
IL262680B2 (en) 2023-08-01
EP3792628A3 (en) 2021-05-19
US20190178871A1 (en) 2019-06-13
EP3792628A2 (en) 2021-03-17
MA43794A (fr) 2019-03-20
CN109073637A (zh) 2018-12-21
LT3455625T (lt) 2021-01-11
RU2018137721A (ru) 2020-06-15
AU2022209286A1 (en) 2022-08-25
AU2017264546A1 (en) 2018-10-18
PT3455625T (pt) 2020-10-22
PL3455625T3 (pl) 2021-01-25
SG11201808495SA (en) 2018-10-30
HUE052240T2 (hu) 2021-04-28
MX2022007902A (es) 2022-07-21
IL262680A (en) 2018-12-31
KR20220020993A (ko) 2022-02-21
MD3455625T2 (ro) 2020-12-31
MX2018013081A (es) 2019-01-24
EP3455625A1 (en) 2019-03-20
DK3455625T3 (da) 2020-10-26
AU2017264546B2 (en) 2022-04-28
ZA201805809B (en) 2020-12-23
WO2017194610A1 (en) 2017-11-16
MA43794B1 (fr) 2020-12-31
CA3022654A1 (en) 2017-11-16
RU2018137721A3 (pt) 2020-08-25
KR102358620B1 (ko) 2022-02-07
JP2022081492A (ja) 2022-05-31
ES2826480T3 (es) 2021-05-18
WO2017194170A1 (en) 2017-11-16
HRP20201671T1 (hr) 2021-03-05
EP3792628B1 (en) 2024-04-24
IL300841A (en) 2023-04-01

Similar Documents

Publication Publication Date Title
BR112018073221A2 (pt) métodos de previsão da utilidade de proteínas ou seus fragmentos, métodos de seleção e/ou avaliação de modificações de aminoácidos específicas, método de fornecimento de vacinas e vacina
MX2022000012A (es) Prediccion de epitopos de celulas t utiles para vacunacion.
AU2018250464B2 (en) Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
MX2021015933A (es) Peptidos y combinacion de peptidos para usarse en la inmunoterapia contra el cancer de prostata y otros tipos de cancer.
EA201891699A3 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии нескольких видов опухолей
EA201791150A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии гепатоклеточной карциномы (гкк) и других видов рака
CR20180027A (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer.
BR112018015545A2 (pt) tratamentos de câncer do útero
EA201792044A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака
PH12017502279A1 (en) Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer and other cancers
MX2018011388A (es) Peptidos novedosos, combinacion de peptidos y soportes para usarse en el tratamiento inmunoterapeutico de varios tipos de cancer.
MX2021001622A (es) Peptidos novedosos y combinacion de peptidos para usarse en inmunoterapia contra diferentes tumores.
WO2016011432A3 (en) Identification of immunogenic mhc class ii peptides for immune-based therapy
AR112601A1 (es) Métodos para predecir la utilidad de modificaciones aminoacídicas específicas de enfermedad para inmunoterapia
PH12016502008A1 (en) Novel immunotherapy against several tumors of the blood, such as acute myeloid lukemia (aml)
EA201990588A1 (ru) Новые пептиды и каркасы для применения в иммунотерапии плоскоклеточной карциномы головы и шеи и других видов рака
EA202190465A3 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии нхл и других видов рака
EA202090821A1 (ru) Новый метод иммунотерапии нескольких видов опухолей, таких как рак легкого, включая нмрл
BR112015028126A8 (pt) Previsão de imunogenicidade de epítopos de células t

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25A Requested transfer of rights approved

Owner name: TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ GEMEINNUETZIGE GMBH (DE) ; BIONTECH SE (DE)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]